Navigation Links
BioXpress Therapeutics SA to Partner the 2011 BIO International Convention
Date:6/15/2011

GENEVA, Switzerland, June 15, 2011 /PRNewswire/ -- BioXpress Therapeutics SA, a Swiss-based biotechnology company developing high-quality monoclonal antibody (MAb) biosimilars announced today representatives from the Company will be partnering at the 2011 BIO International Convention's One-on-One Partnering Meetings being held Jun 27-30 in Washington, D.C. at the Walter E. Washington Convention Center.  

BioXpress Therapeutics currently has 4 biosimilar monoclonal antibody drugs in development with an additional 14 in the pipeline.

Representatives available to discuss partnering opportunities include:  Dr. Cori Gorman and Dr. Curt Scribner.  Companies or individuals attending BIO 2011 can schedule meetings with BioXpress Therapeutics by visiting (registration required):  oneononepartnering.bio.org/BusinessForum2011/Login.aspx.  

BioXpress Therapeutics Partnering Schedule:
Monday, June 27 Business Forum  -  12:00 PM - 5:00 PM
Tuesday, June 28 Business Forum  -  7:00 AM – 6:00 PM
Wednesday, June 29 Business Forum  -  7:00 AM – 6:00 PM
Thursday, June 30 Business Forum  -  7:00 AM – 6:00 PM

Each BioXpress Therapeutics biosimilar MAb is developed under strict non-clinical and clinical guidelines as outlined in the European Medicines Agency's "Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies."   Furthermore, each BioXpress Therapeutics biosimilar goes through a complete analytical comparison to determine the product is similar to the innovator product.

Having the correct primary sequence is absolutely critical for a biosimilar to have similarity and comparability to the innovator drug. Typically, there are several sequences published for every marketed monoclonal antibody. To ensure BioXpress Therapeutics has identified the correct sequence, the Company has developed a proprietary database of protein sequences based on comprehensive analysis of literature and patent databases. All data entry and data analysis is done by the Company's team which consists of scientists who have been actively involved in making monoclonal antibody therapeutics since the early 1980s. As a result, the BioXpress scientific team is well-versed in the literature and groups who have developed many of the originator MAbs over the decades. Based on the data from the BioXpress database, the biosimilar protein is expressed and compared to the originator to ensure a valid sequence before moving the drug forward.

About BioXpress Therapeutics

BioXpress Therapeutics SA is a privately held biotechnology committed to developing and supplying the highest quality and cost-competitive biosimilar biologic API for unmet need indications such as cancer, inflammation and autoimmunity.  Headquartered in Geneva, Switzerland, BioXpress Therapeutics business is focused on developing unbranded monoclonal antibody (MAb and MAb-like) biosimilar drugs under strict European Medicines Agency (EMA) guidelines.

For more information visit www.bioxpress.com.

Media Contact

Robert Meister
602-953-1716
robert@meister.net


'/>"/>
SOURCE BioXpress Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Arcion Therapeutics to Present ARC-4558 Phase 2b Data for the Treatment of Pain Associated With Painful Diabetic Neuropathy at Upcoming Medical Meetings
2. Cell Therapeutics on Preliminary List of Additions to Russell 3000® Index and Russell Global Index
3. Northwest Biotherapeutics Announces Change and Expansion of Management Team
4. Northwest Biotherapeutics Announces Series of Financing Arrangements
5. Healthpoint Biotherapeutics Acquires Regranex® Gel
6. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
7. Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017
8. Juventas Therapeutics Demonstrates JVS-100 Delivery to Patients with Heart Failure is Safe and Provides Clinical Benefit
9. Northwest Biotherapeutics to Present at American Society of Cell and Gene Therapy
10. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
11. Nile Therapeutics to Transition to OTCQB Marketplace
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... , ... April 28, 2017 , ... While things have ... to restructure the company and provide a new outlook for the future. As ... to implement new management with the retirement of Mr. Siegel as CEO. With the ...
(Date:4/27/2017)... SILVER SPRING, Md. and RESEARCH ... -- United Therapeutics Corporation (NASDAQ: UTHR ) ... repurchase of up to $250 million of the company,s ... will remain open through December 31, 2017. Purchases may ... or in privately negotiated transactions from time to time ...
(Date:4/27/2017)... ... April 27, 2017 , ... Proscia ... their digital pathology technology has the potential to eliminate subjectivity in the detection ... The Netherlands as part of the 2017 ISBI CAMELYON Digital Pathology Challenge, ...
(Date:4/27/2017)... , ... April 27, 2017 , ... ... and secure electronic informed consent (eConsent) solution that simplifies research studies, accelerates study ... consulting division of Quorum, Q Consent™ is the first and only IRB-integrated ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
Breaking Biology News(10 mins):